The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Goldman Sachs reiterates a Buy rating on Eli Lilly, pointing to progress in obesity drug development
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 12, 9:29 AM EDT

Goldman Sachs reiterates a Buy rating on Eli Lilly, pointing to progress in obesity drug development

The bank said Eli Lilly’s pipeline momentum and recent regulatory and coverage updates around obesity treatment are sustaining investor interest.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Goldman Sachs reiterated a Buy rating on Eli Lilly and Co. and cited what it called encouraging momentum in the company’s obesity treatment pipeline. The note comes as market attention on Lilly has intensified following a strong stretch for the company’s earnings and obesity-related catalysts.

In recent trading referenced in the report, Eli Lilly’s shares rose by roughly 12% in May 2026. The move was attributed in the post to a strong first-quarter 2026 earnings performance and to new developments tied to its obesity franchise.

A key part of the cited story is regulatory progress. The report said Eli Lilly received U.S. Food and Drug Administration approval for Foundayo, a name the post uses for its obesity treatment. FDA approval typically matters because it opens the door to broader prescribing and commercial uptake, but the company’s detailed terms, utilization, and timeline were not described in the cited post.

The post also pointed to coverage expansion by insurers for obesity treatment. Expanded insurance coverage can reduce patient out-of-pocket costs and improve access, which in turn can affect prescription volumes and revenue. The report did not specify which insurers expanded coverage, how broad the changes were, or whether Lilly saw immediate uptake.

On the financial side, the post attributed the stock move in May largely to a first-quarter 2026 earnings beat. It did not provide the size of the beat, guidance changes, or segment-level results in the information available here, so investors will have to look to the company’s reporting for the underlying drivers.

Eli Lilly, a major U.S. drugmaker, has built a significant pipeline effort around metabolic and obesity indications. In that context, analyst focus often centers on whether drugs can convert from clinical results into sustained real-world demand, supported by reimbursement, manufacturing scale, and competitive positioning. For investors, a “Buy” reiteration generally indicates the analyst expects upside or limited downside relative to peers, but the report excerpt here does not include Lilly’s valuation framework or target price.

What is not clear from the information available in the cited Yahoo Finance post is the specificity of Goldman’s thesis. The post does not spell out which pipeline programs Goldman is most confident in beyond obesity, does not describe any probability-weighting of near-term milestones, and does not state whether the rating change is tied to revisions in earnings estimates or longer-term model assumptions.

Investors watching Eli Lilly next will likely focus on additional regulatory updates, continued insurer coverage expansion, and follow-through after FDA approval for its obesity treatment. On the stock, the pace of uptake and any updated revenue expectations after Lilly’s quarterly reporting would be the practical indicates to monitor. For now, the bank’s stance as described reflects confidence in obesity-related momentum rather than a detailed disclosure of new company guidance.

Why It Matters

  • Analyst reiterations can influence short-term sentiment, especially when they tie the thesis to high-demand therapeutic areas like obesity.
  • FDA approval is often a commercial inflection point, and coverage expansion can determine how quickly prescriptions translate into revenue.
  • Investors will likely look for evidence that regulatory and reimbursement tailwinds show up in Lilly’s reported results, not just in headlines.
  • Without disclosed pricing, uptake, or guidance changes in the referenced post, the near-term market reaction may remain sensitive to subsequent earnings and policy updates.

Sources

Key Facts

  • Goldman Sachs reiterated a Buy rating on Eli Lilly with a stated focus on encouraging obesity-treatment pipeline momentum.
  • Eli Lilly shares were described as rising about 12% during May 2026 in the cited market coverage.
  • The post attributed the May gain to a strong first-quarter 2026 earnings beat.
  • The report said the FDA approved Foundayo, an obesity treatment referenced in the post.
  • The coverage also cited expansion of insurance coverage for obesity treatment as a supporting factor.
  • The Yahoo Finance post did not provide detailed numbers (earnings figures, forecast changes) or insurer-specific details in the information available here.

Healthcare Related

Goldman Sachs reiterates a Buy rating on Eli Lilly, pointing to progress in obesity drug development | The Apex Times